CMMB Chemomab Therapeutics
- 1.713
- +0.063+3.82%
- 1.710
- -0.003-0.18%
Chemomab Therapeutics News
Chemomab Therapeutics Aligns Leadership Incentives With Shareholders
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Cuts Target Price to $11
Chemomab Therapeutics Analyst Ratings
Express News | Chemomab Therapeutics Ltd. : Oppenheimer Cuts Target Price to $11 From $13
Chemomab Therapeutics Sees Cash Runway Through Beginning of 2026
Express News | Chemomab Therapeutics Q3 2024 GAAP EPS $(0.20) Misses $(0.01) Estimate
Chemomab Therapeutics 3Q EPS 1c >CMMB
Earnings Scheduled For November 14, 2024
Earnings Preview: CMMB to Report Financial Results Pre-market on November 14
Express News | Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $9
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Express News | Chemomab Therapeutics Announces Late-Breaking Oral Presentation of Cm-101 Phase 2 Results in Primary Sclerosing Cholangitis at Aasld the Liver Meeting® 2024
Chemomab Therapeutics Announces Shareholder Meeting
Express News | Carl L. Gordon Reports 9.99% Stake in Chemomab Therapeutics as of Sept 12 Vs 16.0% as Reported in March 11 - SEC Filing
ADRs Close Lower; Chemomab Therapeutics Ltd. Declines 17%
Express News | Chemomab Therapeutics Ltd Files for Resale of up to 8.1 Mln Adss by the Selling Shareholders - SEC Filing
Chemomab Therapeutics (CMMB) Gets a Buy From Oppenheimer
Express News | Chemomab Says Existing Liquidity Resources Of $12.8M As Of June 30, 2024, Together With The Additional Funds Of Approximately $10M Raised In July 2024, Will Enable The Company To Fund Its Operations Through The Beginning Of 2026
No Data